Acadian Asset Management’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Acadian Asset Management’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-143	Closed	-$36K	–	1648
2021 Q4	$36K	Sell	143 -431	-75%	-$119K	﹤0.01%	1531
2021 Q3	$189K	Buy	+574	New	+$226K	﹤0.01%	1307
2018 Q2	–	Sell	-4	Closed	-$15K	–	1711
2018 Q1	$15K	Buy	+4	New	+$22.1K	﹤0.01%	1517

Other funds holding CANF

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Acadian Asset Management's CANF Position: Q1 2022 in Review

Acadian Asset Management sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q1 2022, closing a stake of 143 shares — an estimated $36K sold.

Acadian Asset Management first reported a position in CANF in Q1 2018 and held it in 3 quarters. The position peaked at $189K in Q3 2021. 13 funds tracked by Wall St. Rank hold CANF as of Q1 2022.

Acadian Asset Management reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q1 2022 after selling out during the quarter.
Acadian Asset Management sold 143 Can-Fite BioPharma American Depositary Shares shares in Q1 2022, an estimated $36K.
Acadian Asset Management first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2018 and held it in 3 quarters.
Acadian Asset Management's Can-Fite BioPharma American Depositary Shares position peaked at $189K in Q3 2021.
13 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q1 2022.

Based on Acadian Asset Management's 13F filing for Q1 2022, filed 12 May 2022.